Stergiou Angelos M.
Transaction: 06/16/2026
BUY
Change
+1,065,000
Price
Not reported
Filing
06/18/2026
Type
BUY
SELLAS Life Sciences Group, Inc.
SLS • Biotechnology
$13.86
— 0.00 (0.00%)
EarningsLatest report: Mar 31, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$2.39B
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.01Healthy liquidity · 10.72Negative growth trendWeak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 12, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$13.86
Change0.00%
Shares Out172.48M
Market Cap$2.39B
Enterprise Value$2.28B
52W Range1.39 - 11.06
Beta2.53
P/E-81.16
P/B22.26
P/FCF-84.88
EV/EBITDA-95.91
EV/FCF-81.10
Price$13.86
Change0.00%
Shares Out172.48M
Market Cap$2.39B
Enterprise Value$2.28B
52W Range1.39 - 11.06
Beta2.53
P/E-81.16
P/B22.26
P/FCF-84.88
EV/EBITDA-95.91
EV/FCF-81.10
Earnings Yield-1.23%
FCF Yield-1.18%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.01
Current Ratio10.72
Quick Ratio10.72
Target$35.00
Target Upside152.53%
Target Median$35.00
Target Range35.00 - 35.00
Volume14.95M
Avg Volume7.48M
EPS Surprise0.01
Investment DNA
How strong this company looks for long-term investors
35
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
55/100
Why this score▼
Manageable debt level · 0.01Healthy liquidity · 10.72Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 5 analyst votes · 2026-09-05
100/100
Bullish
Bullish
5
Hold
0
Bearish
0
Price Target
2026-06-26
Low
$2.40
Mean
$2.80
Median
$2.80
High
$3.20
Insider Transactions
Recent executive and insider activity
⚠ 1 high-volume insider sell detected
Wasman Jane
Transaction: 01/07/2026
BUY
Change
+50,000
Price
Not reported
Filing
01/09/2026
Type
BUY
Kalin Katherine Bach
Transaction: 01/07/2026
BUY
Change
+50,000
Price
Not reported
Filing
01/09/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Stergiou Angelos M. | BUY | +1,065,000 | Not reported | 06/16/2026 | 06/18/2026 |
| Wasman Jane | BUY | +50,000 | Not reported | 01/07/2026 | 01/09/2026 |
| Kalin Katherine Bach | BUY | +50,000 | Not reported | 01/07/2026 | 01/09/2026 |
| Burns John Thomas | BUY | +300,000 | Not reported | 01/07/2026 | 01/09/2026 |
| CICIC DRAGAN | BUY | +300,000 | Not reported | 01/07/2026 | 01/09/2026 |
| SCHEINBERG DAVID A | BUY | +50,000 | Not reported | 01/07/2026 | 01/09/2026 |
| VAN NOSTRAND ROBERT L | BUY | +50,000 | Not reported | 01/07/2026 | 01/09/2026 |
| Varian John | BUY | +50,000 | Not reported | 01/07/2026 | 01/09/2026 |
| Stergiou Angelos M. | SELL | -187,066 | $1.50 | 12/03/2025 | 12/05/2025 |
| Burns John Thomas | SELL | -58,592 | $1.50 | 12/03/2025 | 12/05/2025 |
| CICIC DRAGAN | SELL | -63,800 | $1.50 | 12/03/2025 | 12/05/2025 |
| Kalin Katherine Bach | BUY | +63,400 | $1.59 | 11/19/2025 | 11/21/2025 |
| VAN NOSTRAND ROBERT L | BUY | +10,000 | $1.48 | 06/12/2025 | 06/13/2025 |
| Wasman Jane | BUY | +20,000 | $1.69 | 05/30/2025 | 06/02/2025 |
| Kalin Katherine Bach | BUY | +20,000 | $1.80 | 05/22/2025 | 05/22/2025 |
| CICIC DRAGAN | BUY | +169,500 | $0.95 | 01/10/2025 | 01/14/2025 |
| CICIC DRAGAN | BUY | +113,000 | Not reported | 01/10/2025 | 01/14/2025 |
| Varian John | BUY | +18,500 | $0.95 | 01/10/2025 | 01/14/2025 |
| Varian John | BUY | +12,500 | Not reported | 01/10/2025 | 01/14/2025 |
| Kalin Katherine Bach | BUY | +18,500 | $0.95 | 01/10/2025 | 01/14/2025 |